NVCT
Nuvectis Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.47
−4.50%Nov 2, 2026, 22:00 UTC
Nuvectis Pharma announced that it will host a conference call and webcast on November 4, 2026, at 8:00 a.m. ET to discuss business progress and third-quarter financial results.
Source:Oct 26, 2026, 12:30 UTC
Nuvectis Pharma, Inc. reported Phase 1b study data for NXP200, with objective response rates of 40.0% in high-grade glioma and 42.9% in low-grade glioma.
Source:Aug 4, 2026, 00:00 UTC
Nuvectis Pharma reported a net loss of $7.0 million for Q2 2026, compared to a net loss of $6.3 million in Q2 2025.
Jun 29, 2026, 20:01 UTC
Nuvectis Pharma, Inc. announced an underwritten public offering of its common stock, with an option for underwriters to purchase additional shares.
Jun 22, 2026, 11:48 UTC
Nuvectis entered into a license agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 and NXP200.